Paloma Partners’s AstraZeneca AZN Stock Holding History

Paloma Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,656	Closed	-$237K	–	2142
2019 Q3	$237K	Buy	+2,656	New	+$230K	﹤0.01%	1665
2018 Q3	–	Sell	-3,800	Closed	-$267K	–	1542
2018 Q2	$267K	Buy	3,800 +823	+28%	+$59.2K	﹤0.01%	1336
2018 Q1	$208K	Buy	+2,977	New	+$206K	﹤0.01%	1783
2015 Q1	–	Sell	-15,000	Closed	-$1.06M	–	1191
2014 Q4	$1.06M	Hold	15,000	–	–	0.05%	416
2014 Q3	$1.07M	Sell	15,000 -35,000	-70%	-$2.56M	0.05%	334
2014 Q2	$3.72M	Buy	50,000 +39,672	+384%	+$2.87M	0.15%	145
2014 Q1	$670K	Buy	+10,328	New	+$667K	0.04%	303

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Paloma Partners's AZN Position: Q4 2019 in Review

Paloma Partners sold out of AstraZeneca (AZN) in Q4 2019, closing a stake of 2,656 shares — an estimated $237K sold.

Paloma Partners first reported a position in AZN in Q1 2014 and held it in 7 quarters. The position peaked at $3.72M in Q2 2014. 634 funds tracked by Wall St. Rank hold AZN as of Q4 2019.

Paloma Partners reported no remaining AstraZeneca position as of Q4 2019 after selling out during the quarter.
Paloma Partners sold 2,656 AstraZeneca shares in Q4 2019, an estimated $237K.
Paloma Partners first reported a position in AstraZeneca in Q1 2014 and held it in 7 quarters.
Paloma Partners's AstraZeneca position peaked at $3.72M in Q2 2014.
634 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.